Amyris
Precision-fermentation and biomanufacturing services for companies developing renewable chemicals and ingredients
Highlights
- New on EvolcAdded 2026-11-14
Recent signals
What changed at Amyris in the last 6 months, newest first. Each line links to its public source.
- 12 Nov 2026 Publishing · Restarted publishing: 3 blog or news posts in 30 days amyris.com
- 9 Nov 2026 Leadership hire · Hiring Director, Global IT Infrastructure and Operations (Emeryville) job-boards.greenhouse.io
About Amyris
Amyris uses precision fermentation, synthetic biology and renewable biological chemistry to develop and manufacture molecules from plant-derived feedstocks. Its services include strain design, fermentation, purification, scale-up and supply, alongside a portfolio of fermentation-derived ingredients and building blocks.
Customers include companies seeking biotechnology-derived ingredients or manufacturing partners, including in personal care, fragrance, specialty chemicals and other markets. Amyris works with partners on product development and commercial production.
Founded in 2003, Amyris is headquartered in Emeryville, California, and operates manufacturing plants in Brazil, including Barra Bonita and Brotas. Its open roles span US facilities, laboratory, IT and automation positions, as well as manufacturing and engineering roles in Brazil.
Product: Precision-fermentation development and manufacturing services, plus renewable molecules and biotechnology-derived ingredients.
Jobs at Amyris
Open roles at Amyris in the Americas (8)
United States 4 · Brazil 4. From Amyris's careers page or applicant tracking system; each role links to the employer.
- Técnico Mecânico · Barra Bonita, Brazil
- Senior Facilities Engineer Technician · Emeryville, United States
- QA/QC Laboratory Technician I · Leland, United States
- Lab Automation Engineer II · Emeryville, United States
- Estágio Graduação em Fermentação - Campinas/SP · Campinas, Brazil
- Estágio em Engenharia e Projetos · Barra Bonita, Brazil
- Estágio em Automação Industrial · Barra Bonita, Brazil
- Director, Global IT Infrastructure and Operations · Emeryville, United States
More biotech & pharma companies
Annexon Biosciences
Develops C1q-targeting therapies for patients with complement-driven autoimmune, neurodegenerative and ophthalmic diseasesNew on EvolcAnthrogen
AI biology research lab developing programmable molecular tools and protein models for biological research and interventionNew on EvolcArcaea
Biotechnology research and beauty product development for the beauty industry and consumersNew on EvolcArkeabio
Develops a methane-reducing vaccine for cattle to cut livestock emissions for farmers and food producersNew on EvolcAscendis Pharma
Biopharmaceutical therapies for patients with rare endocrine diseases and other medical needsAsimov
Genetic design software, engineered cells and DNA tools for biotechnology and therapeutics developersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WebflowHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Recruiting
- GreenhouseMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
